Merck Gives Earnings Update Oct. 21, Pfizer Oct. 20
This article was originally published in The Pink Sheet Daily
Executive Summary
Impact of Merck’s Vioxx withdrawal is likely to surface during both companies’ presentations; Merck will present data on Vioxx 25 mg at a rheumatology conference earlier in the week.
You may also be interested in...
Pfizer Sees Increased Cardiovascular Risk With Bextra After Bypass Surgery
Two studies on short-term use of a parecoxib/Bextra treatment regimen following coronary artery bypass graft surgery showed an increased risk of cardiovascular events. Pfizer discusses the surgery study results as part of a "Dear Health Care Professional" letter about skin reactions associated with Bextra.
Arcoxia Safety Can Be Addressed In Labeling, Merck Says
Merck is working with international regulatory agencies on appropriate labeling changes to reflect cardiovascular safety issues that prompted withdrawal of Vioxx. Arcoxia's cardiovascular safety profile is strong for "short-term use," Merck says.
FDA Has One Month To Mull Approval Of Merck's Arcoxia Following Vioxx Withdrawal
Arcoxia's user fee date is Oct. 30, but FDA could decide to wait for 18-month cardiovascular safety data from a 20,000-patient trial comparing etoricoxib with diclofenac. Merck says it will work with regulatory authorities in 47 countries where Arcoxia is marketed to discuss potential labeling changes resulting from the Vioxx study data.